FAP and neoplasm: Of the synthesized FAP molecules, FAP-2286 was identified as a promising tracer for clinical Phase I studies because FAP-2286 maintained higher tumor selectivity and efficacy in comparison to FAPI-46 in pre-clinical models [64,65].